<DOC>
	<DOCNO>NCT01526733</DOCNO>
	<brief_summary>The purpose study evaluate consistency accelerate insulin absorption onset-of-action shorten duration action bolus insulin infusion pretreatment 150 unit ( U ) Hylenex® ( recombinant human hyaluronidase PH20 [ rHuPH20 ] ) injection time infusion set insertion compare sham injection .</brief_summary>
	<brief_title>Randomized , Double Blind , 2 Way Crossover Study CSII With , Versus Without , Pretreatment With Human Hyaluronidase</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>1 . Males females age 18 65 year , inclusive . Females childbearing potential must use standard effective mean birth control duration study . 2 . Nonsmoking participant Type 1 diabetes mellitus ( T1DM ) treat insulin ≥12 month . Nonsmoking mean abstinence cigarettes cigar 3 month negative cotinine screening test screen . 3 . Body mass index ( BMI ) 18.0 35.0 kilogram per meter square ( kg/m² ) , inclusive . 4 . Glycosylated hemoglobin A1c ( HbA1c ) ≤10 % base local laboratory result . 5 . Fasting connect peptide insulin ( Cpeptide ) &lt; 0.6 nanogram per milliliter ( ng/mL ) . 6 . Current treatment insulin &lt; 90 unit per day ( U/d ) . 7 . Current use rapid act insulin analog . 8 . Routine use CSII primary route insulin administration least 3 month prior screen 9 . Participants good general health base medical history physical examination without medical condition might prevent completion study drug infusion assessment require study protocol . 1 . Known suspected allergy component study drug study . 2 . Previous enrollment study . 3 . Use drug may interfere interpretation study result know cause clinically relevant interference insulin action , glucose utilization , recovery hypoglycemia . Participants take maintenance dos blood thinner ( example , coumadin heparin ) exclude . 4 . Use longacting insulin injection within 72 hour Study Day 1 ; participant continue refrain use throughout duration study ( Phases I II ) . 5 . Recurrent major hypoglycemia hypoglycemic unawareness , judge Investigator . 6 . Current addiction alcohol substance abuse determine Investigator . 7 . Blood donation phlebotomy ( &gt; 500 milliliter [ mL ] ) within previous 8 week Screening Visit ( ) study . 8 . Pregnancy , breastfeeding , intention become pregnant , use adequate contraceptive measure ( adequate contraceptive measure consist sterilization , intrauterine device [ IUD ] , oral injectable contraceptive , barrier method ) . 9 . Symptomatic gastroparesis . 10 . Receipt investigational drug within 4 week Study Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Continuous Subcutaneous Insulin Infusion ( CSII )</keyword>
</DOC>